E
Elena N Simakina
Publications - 9
Citations - 253
Elena N Simakina is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 3 publications receiving 117 citations.
Papers
More filters
Journal ArticleDOI
AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial.
Andrey Alexandrovich Ivashchenko,Kirill A. Dmitriev,Natalia V. Vostokova,Valeria N Azarova,Andrew A. Blinow,Alina N. Egorova,Ivan G. Gordeev,Alexey P. Ilin,Ruben N. Karapetian,Dmitry V. Kravchenko,Nikita V. Lomakin,Elena A. Merkulova,Natalia A. Papazova,Elena P. Pavlikova,Nikolay Filippovich Savchuk,Elena N Simakina,Tagir A. Sitdekov,Elena A Smolyarchuk,Elena G. Tikhomolova,Elena V Yakubova,Alexandre V. Ivachtchenko +20 more
TL;DR: In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.
Posted ContentDOI
AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey Alexandrovich Ivashchenko,Kirill A. Dmitriev,Natalia V. Vostokova,Valeria N Azarova,Andrew A. Blinow,Alina N. Egorova,Ivan G. Gordeev,Alexey P. Ilin,Ruben N. Karapetian,Dmitry V. Kravchenko,Nikita V. Lomakin,Elena A. Merkulova,Natalia A. Papazova,Elena P. Pavlikova,Nikolay Filippovich Savchuk,Elena N Simakina,Tagir A. Sitdekov,Elena A Smolyarchuk,Elena G. Tikhomolova,Elena V Yakubova,Alexandre V. Ivachtchenko +20 more
TL;DR: In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients.
Journal ArticleDOI
Effect of Aprotinin and Avifavir ® Combination Therapy for Moderate COVID-19 Patients.
Andrey Alexandrovich Ivashchenko,Valeria N Azarova,Alina N. Egorova,Ruben N. Karapetian,Dmitry V. Kravchenko,Natalia V Krivonos,Vladimir G Loginov,Stanislav V Poyarkov,Elena A. Merkulova,Olga S Rosinkova,Nikolay Filippovich Savchuk,Mikhail A Topr,Elena N Simakina,Elena V Yakubova,Alexandre V. Ivachtchenko +14 more
TL;DR: In this paper, the authors studied the efficacy of Aprotinin (nonspecific serine proteases inhibitor) in combination with Avifavir® or Hydroxychloroquine (HCQ) drugs, which are recommended by the Russian Ministry of Health for the treatment therapy of moderate COVID-19 patients.
Journal ArticleDOI
Effectiveness and safety of favipiravir infusion in patients hospitalized with covid-19
L. A. Balykova,Kira Yа Zaslavskaya,V. F. Pavelkina,Nikolay A. Pyataev,N. M. Selezneva,N. V. Kirichenko,Anastasia Ivanova,G.V. Rodoman Rodoman,Konstantin Kolontarev,K. S. Skrupsky,Elena N Simakina,O. A. Mubarakshina,A. V. Taganov,Dmitry Pushkar +13 more
TL;DR: The versatility and resistance to mutations of RNA-dependent RNA polymerase make it possible to consider it as the main target for combating the most common RNA viruses that cause ARVI, that determines the need for further studies of favipiravir to expand the range of its indications.
Journal ArticleDOI
Modern directed antiviral covid-19 therapy: results of multicenter clinical effectiveness and safety study of fixed nirmatrelvir+ritonavir combination
L. A. Balykova,N. M. Selezneva,E. I. Gorshenina,O. I. Shepeleva,N. V. Kirichenko,Elena N Simakina,Konstantin Kolontarev,Dmitry Pushkar,D. N. Zemskov,Kira Yа Zaslavskaya,S M Noskov,A. V. Taganov,P. A. Bely +12 more
TL;DR: In this paper , the authors presented the data from an open, two-stage, multicenter study on the efficacy and safety evaluation of a combined drug (a fixed combination of nirmatrelvir 300 mg and ritonavir 100 mg) in the complex therapy in COVID-19 patients.